PD-1 and PD-L1

Class

PD-1 x PD-L1 bispecific antibody (immune checkpoint inhibitor)

Pathway

Dual PD-1/PD-L1 axis blockade restoring anti-tumor T-cell activity

PD-1 is an inhibitory receptor expressed on activated T cells, and PD-L1 is its ligand, commonly found on tumor cells and antigen-presenting cells. Their interaction dampens T-cell activity, a normal safeguard against autoimmunity that many cancers exploit to blunt immune surveillance. Blocking this axis, known as immune checkpoint inhibition, removes that brake and allows T cells to recognize and attack tumor cells more effectively. This mechanism uses a bispecific antibody engineered to bind both PD-1 and PD-L1 simultaneously, rather than targeting only one side of the interaction. Combining both binding specificities in one molecule can produce more complete disruption of the checkpoint, since it can engage receptor and ligand wherever they are found, including on different cells within the tumor microenvironment. This approach is relevant across a broad range of solid tumors and some hematologic cancers where PD-L1 expression or T-cell exhaustion contributes to immune evasion. Checkpoint blockade of this kind has become a foundational strategy in oncology, applicable alone or alongside other therapies aimed at boosting anti-tumor immunity. Because the mechanism depends on releasing a natural immune restraint, it must be balanced against the risk of excessive immune activation elsewhere in the body.